Acute Myeloid Leukemia (AML)

Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML

Original Publication Date
Article Source
External Web Content
Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut, discusses updated results from an ongoing retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in patients with relapsed/refractory…

Outcomes of Adding a Fourth Chemotherapy Course in AML

Original Publication Date
Article Source
External Web Content
Administering 2 additional courses of chemotherapy with high-dose cytarabine (Ara-C) after 2 courses of induction therapy improved relapse rates but did not improve overall survival for patients with acute myeloid leukemia (AML), according to research in the Journal of Clinical…

Precision Medicine Approach Deemed Safe, Feasible for Older Patients With Untreated AML

Original Publication Date
Article Source
External Web Content
A precision medicine treatment approach that incorporates genomic data into treatment decisions appears to be feasible in older patients with untreated acute myeloid leukemia (AML), according to a study published in Nature Medicine. Investigators also found that delaying…

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

Original Publication Date
Article Source
External Web Content
TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival. Across TP53-altered MDS and AML…

Martha L. Arellano, MD

Institution
Emory University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
About
Martha L. Arellano, MD, is an Associate Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine where she serves as Associate Director of the Division of Hematology. Board certified in hematology, medical oncology and internal medicine, Dr. Arellano specializes in the treatment of leukemia and myelodysplastic syndromes. She started practicing with Emory Healthcare in 2006. Dr. Arellano is a clinical member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. She currently leads the

Guadecitabine Maintenance Therapy Shows Promise in High Risk MDS/AML Patients

Original Publication Date
Article Source
External Web Content
Guadecitabine (SGI-110), when given as maintenance therapy following allogeneic stem cell transplantation (allo-SCT), showed promising relapse-free survival rates (RFS) with manageable safety in high-risk patients with myelodysplastic syndromes/acute myeloid leukemia (MDS/AML)…

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

Original Publication Date
Article Source
External Web Content
December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia. GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk…

Oral Azacitidine Improves, Sustains Health-Related QoL in AML

Original Publication Date
Article Source
External Web Content
Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial. Treatment with oral azacitidine (CC-486) showed sustained health-related quality…

Significant Racial, Ethnic Related Socioeconomic Disparities Influence Survival in AML

Original Publication Date
Article Source
External Web Content
Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area. Significant disparities were found…
Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.